Read more

January 24, 2023
1 min read
Save

Top in ID: Long COVID in adults; changes in antibiotic prescribing

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Nearly 19 million adults in the United States may have long COVID, with some individuals reporting symptoms more than 1 year following their infection, according to results of a population-based study.

“Most studies of long COVID are in select samples of people, such as people hospitalized with COVID or people who seek health care for COVID symptoms or long COVID symptoms, but there were no studies that tried to get at what the true burden of long COVID is in the general population,” Denis Nash, PhD, MPH, executive director of City University of New York Institute for Implementation Science in Population Health and distinguished professor of epidemiology at the CUNY School of Public Health, told Healio.

COVID-19 test tube being held by someone
Nearly 19 million adults in the United States may have long COVID, with some individuals reporting symptoms more than 1 year following their infection, according to results of a population-based study. Source: Adobe Stock

It was the top story in infectious disease last week.

Another top story was about research showing that the shorter durations of antibiotic therapy are just as effective as longer courses for many infections.

Read these and more top stories in infectious disease below:

Survey results indicate nearly 19 million US adults may have long COVID

The results of a population-based survey suggest that nearly 19 million U.S. adults may have long COVID, with some reporting symptoms more than 12 months after their initial infection. Read more.

‘Shorter is better’ mantra begins to change antibiotic prescribing

The optimal duration of antibiotic therapy has been a matter of some debate, and increasingly, research is showing that shorter durations are just as effective as longer courses for many infections. Read more.

Safety signal for COVID-19 booster unlikely to be ‘true clinical risk,’ officials say

Health officials said a safety signal detected by a national surveillance system is “very unlikely” to represent a “true clinical risk” for stroke among older people who received the Pfizer-BioNTech bivalent COVID-19 booster. Read more.

Covering N95 respirator with face mask can increase risk of leakage

Covering N95 filtering facepiece respirators with a face mask can cause respirator leaking and failure, according to a study among health care workers. Read more.

Moderna phase 3 trial shows RSV vaccine safe, effective in older adults

Moderna announced that its RNA-based respiratory syncytial virus vaccine has met primary endpoints in a phase 3 trial showing that the vaccine is both safe and highly effective in older adults. Read more.